Shariq S. Ansari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shariq S. Ansari has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Anirban Maitra
Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York City, New York, USA
19 shared publications - Benson Chellakkan Selvanesan
The University of Texas MD Anderson Cancer Center 1 Department of Translational Molecular Pathology Houston, Texas
19 shared publications - Bidyut Ghosh
The University of Texas MD Anderson Cancer Center 1 Department of Translational Molecular Pathology Houston, Texas
19 shared publications - Cara Haymaker
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
19 shared publications - Ching-Fei Li
Department of Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
19 shared publications - Dorsay Sadeghian
Baylor College of Medicine 3 Department of Pathology and Immunology Houston, Texas
19 shared publications
Latest Publications
- Open Access
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
CyTOF Antibody Panel: Information about antibodies used in CyTOF experiment, their target, source, clones, and cat. no.
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
CyTOF Antibody Panel: Information about antibodies used in CyTOF experiment, their target, source, clones, and cat. no.
- Open Access
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Related to Figure 2: effect of KDM4C KO on the proliferation of HPNE cells.
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Related to Figure 2: effect of KDM4C KO on the proliferation of HPNE cells.
- Open Access
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Related to Figure 6: KDM4C-miniTurboID validation, Heatmaps for H3K36me3 and H3K27Ac ChIPseq in KDM4C KO vs WT AsPC1, and DUSP2 knockdown western panel.
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Related to Figure 6: KDM4C-miniTurboID validation, Heatmaps for H3K36me3 and H3K27Ac ChIPseq in KDM4C KO vs WT AsPC1, and DUSP2 knockdown western panel.
- Open Access
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
PCR primer sequences: Sequence information for forward and reverse primers used to detect mRNA levels of DUSP1, DUSP2, DUSP4, DUSP5, and DUSP6.
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
PCR primer sequences: Sequence information for forward and reverse primers used to detect mRNA levels of DUSP1, DUSP2, DUSP4, DUSP5, and DUSP6.
- Open Access
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Related to Figure 4: KDM4C depletion increases immune surveillance in vivo.
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Related to Figure 4: KDM4C depletion increases immune surveillance in vivo.
- Open Access
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
KDM4C expression correlates with ERK activity. A, Top enriched IPA pathways from RNA-seq data from KDM4C KO vs. WT AsPC1 are cell-cycle arrest, inhibition of MEK/ERK, protein synthesis inhibition, and increased oxidative phosphorylation and apoptosis, whereas ATF4, MYC, and ERK1/2 are among the top downregulated networks. B, GSEA plot from RNA-seq data showing downregulated KRAS and MYC signatures in KDM4C-depleted cells. C, RPPA data demonstrate downregulation of the ERK pathway in two different KDM4C-null clones. D, Western blot validating downregulation of ERK phosphorylation in human PDAC cell line AsPC1 and in mouse PDAC cell line (KPC-mT4) KDM4C KO clones. E, Representative micrographs of pERK expression by IHC in PDAC tumors harvested at day 30 from mice injected with PDAC cell line KPC-mT4 demonstrates downregulation of pERK in the KDM4C KO clones compared with untreated KPC-mT4 (Scale bar, 100 μm).
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
KDM4C expression correlates with ERK activity. A, Top enriched IPA pathways from RNA-seq data from KDM4C KO vs. WT AsPC1 are cell-cycle arrest, inhibition of MEK/ERK, protein synthesis inhibition, and increased oxidative phosphorylation and apoptosis, whereas ATF4, MYC, and ERK1/2 are among the top downregulated networks. B, GSEA plot from RNA-seq data showing downregulated KRAS and MYC signatures in KDM4C-depleted cells. C, RPPA data demonstrate downregulation of the ERK pathway in two different KDM4C-null clones. D, Western blot validating downregulation of ERK phosphorylation in human PDAC cell line AsPC1 and in mouse PDAC cell line (KPC-mT4) KDM4C KO clones. E, Representative micrographs of pERK expression by IHC in PDAC tumors harvested at day 30 from mice injected with PDAC cell line KPC-mT4 demonstrates downregulation of pERK in the KDM4C KO clones compared with untreated KPC-mT4 (Scale bar, 100 μm).
- Open Access
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Compensatory upregulation of KDM4A restores cell-intrinsic ERK signaling in KDM4C-null cells but not immune surveillance. A, Western blot panel shows that late-passage KDM4C KO clones of both AsPC1 and KPC-mT4 (KO-late) restored pERK levels. B–D, ERK reactivation rescues the reduction in colony formation and proliferation in both AsPC1 and KPC-mT4 KO cells observed in earlier passages. Bar plots show number of colonies calculated by ImageJ. For each sample, two wells have been analyzed, and the statistical significance is calculated using one-way ANOVA. For both AsPC1 and KPC-mT4 cells, the difference between parental and adapted KDM4C KO clones was not significant. E, Lentiviral shRNA knockdown of KDM4C recapitulates the adaptation to KDM4C depletion in adapted cells. Western blot panel compares early-passage (day 7 after transduction) and late-passage (day 40 after transduction) in AsPC1 cells. Late-passage KDM4C knockdown cells have adapted to the loss of KDM4C and restored ERK activation. F, Western blot validating KDM4A upregulation in adapted KPC-mT4 KDM4C KO clones. G, RNA-seq results from AsPC1 early-passage KDM4C KO cells correlate with the ERK inhibitor (ERKi) transcriptome signature, whereas late-passage adapted cells are inversely correlated. H and I, Bar graphs showing significant reduction in the tumor growth of adapted KPC-mT4 KDM4C KO cells when transplanted into the immunocompetent B6 mice compared with KDM4C WT control (n = 5), whereas the reverse is observed when the same cells are transplanted into immune-compromised athymic mice (n = 8), significance determined by unpaired t test; *, P ≤ 0.05.
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Compensatory upregulation of KDM4A restores cell-intrinsic ERK signaling in KDM4C-null cells but not immune surveillance. A, Western blot panel shows that late-passage KDM4C KO clones of both AsPC1 and KPC-mT4 (KO-late) restored pERK levels. B–D, ERK reactivation rescues the reduction in colony formation and proliferation in both AsPC1 and KPC-mT4 KO cells observed in earlier passages. Bar plots show number of colonies calculated by ImageJ. For each sample, two wells have been analyzed, and the statistical significance is calculated using one-way ANOVA. For both AsPC1 and KPC-mT4 cells, the difference between parental and adapted KDM4C KO clones was not significant. E, Lentiviral shRNA knockdown of KDM4C recapitulates the adaptation to KDM4C depletion in adapted cells. Western blot panel compares early-passage (day 7 after transduction) and late-passage (day 40 after transduction) in AsPC1 cells. Late-passage KDM4C knockdown cells have adapted to the loss of KDM4C and restored ERK activation. F, Western blot validating KDM4A upregulation in adapted KPC-mT4 KDM4C KO clones. G, RNA-seq results from AsPC1 early-passage KDM4C KO cells correlate with the ERK inhibitor (ERKi) transcriptome signature, whereas late-passage adapted cells are inversely correlated. H and I, Bar graphs showing significant reduction in the tumor growth of adapted KPC-mT4 KDM4C KO cells when transplanted into the immunocompetent B6 mice compared with KDM4C WT control (n = 5), whereas the reverse is observed when the same cells are transplanted into immune-compromised athymic mice (n = 8), significance determined by unpaired t test; *, P ≤ 0.05.
- Open Access
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
CRISPR-mediated KDM4C deletion attenuates PDAC growth in vitro and in vivo. A, Western blot showing KDM4C depletion in selected AsPC1 and KPC-mT4 KDM4C-null clones. B, Colony formation assay (CFA): representative wells comparing AsPC1 cells to KDM4C KO isogenic cells show reduced colony formation ability in the absence of KDM4C. C, Quantification of CFA by ImageJ shows a significant reduction in the number of colonies in KDM4C KO cells compared with KDM4C WT cells; P value was determined by one-way ANOVA test; *, P ≤ 0.05; **, P ≤ 0.01. D, Proliferation assay measured through % confluence over time by the Incucyte Live Imaging system shows decreased proliferation in the absence of KDM4C, P value determined by one-way ANOVA test. E, Kaplan–Meier survival plot showing increased survival of B6 mice orthotopically transplanted with KDM4C KO KPC-mT4 cells compared with those transplanted with KDM4C WT KPC-mT4 (n = 6 per arm).
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
CRISPR-mediated KDM4C deletion attenuates PDAC growth in vitro and in vivo. A, Western blot showing KDM4C depletion in selected AsPC1 and KPC-mT4 KDM4C-null clones. B, Colony formation assay (CFA): representative wells comparing AsPC1 cells to KDM4C KO isogenic cells show reduced colony formation ability in the absence of KDM4C. C, Quantification of CFA by ImageJ shows a significant reduction in the number of colonies in KDM4C KO cells compared with KDM4C WT cells; P value was determined by one-way ANOVA test; *, P ≤ 0.05; **, P ≤ 0.01. D, Proliferation assay measured through % confluence over time by the Incucyte Live Imaging system shows decreased proliferation in the absence of KDM4C, P value determined by one-way ANOVA test. E, Kaplan–Meier survival plot showing increased survival of B6 mice orthotopically transplanted with KDM4C KO KPC-mT4 cells compared with those transplanted with KDM4C WT KPC-mT4 (n = 6 per arm).
- Open Access
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
KDM4C shRNA sequences: Oligo ID and sequence information for the shRNA used to knockdown KDM4C.
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
KDM4C shRNA sequences: Oligo ID and sequence information for the shRNA used to knockdown KDM4C.
- Open Access
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
CRISPR sgRNA sequences: sequence information for sgRNAs used to knockout KDM4C in human and mouse PDAC cell lines.
- 30 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
CRISPR sgRNA sequences: sequence information for sgRNAs used to knockout KDM4C in human and mouse PDAC cell lines.